NANOSCOPE PRESS RELEASE

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

  • MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events
  • Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of the retina
  • RESTORE is the first randomized, controlled trial of a mutation-agnostic gene therapy for a genetic disease
  • Nanoscope anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024